Evidence map›Paper›PMID 39536313›Full record

ArticleJMIR public health and surveillance2024

Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study.

Duygu Islek, Travis Sanchez, Jennifer L Glick, Jeb Jones, Keith Rawlings, Supriya Sarkar, Patrick S Sullivan, Vani Vannappagari

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Duygu IslekRollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID 0000-0001-6041-2320
Travis SanchezRollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID 0000-0003-1133-4762
Jennifer L GlickCommunity Health Science & Policy (CHSP), LSUHSC, New Orleans, LA, United States.ORCID 0000-0003-3323-1983
Jeb JonesRollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID 0000-0001-9165-1658
Keith RawlingsViiV Healthcare, Durham, NC, United States.ORCID 0009-0007-5545-421X
Supriya SarkarViiV Healthcare, Durham, NC, United States.ORCID 0000-0001-8495-5039
Patrick S SullivanRollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID 0000-0002-7728-0587
Vani VannappagariViiV Healthcare, Durham, NC, United States.ORCID 0000-0002-0157-9689

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

backgroundLong-acting (LA) injectable preexposure prophylaxis (PrEP) and on-demand PrEP may improve overall PrEP uptake among men who have sex with men (MSM), but little is understood about the PrEP option preferences of MSM in practical scenarios where they may choose between various PrEP options.

objectiveThis study aims to examine the preferences for starting various PrEP options among a US nationwide online convenience sample of MSM from September 2021 to February 2022.

methodsParticipants reporting no prior HIV diagnosis were provided brief descriptions of each PrEP option and were asked, "If [PrEP option] were available from your local doctor and you could access it for free, would you go to your doctor in the next month to start [PrEP option]?" Those who said "yes" to multiple options were asked to rank them in order of preference. MSM currently taking daily oral (DO) PrEP were asked whether they would switch to on-demand or LA PrEP options. Log binomial models were created to examine the association between willingness to start or switch to on-demand and LA PrEP with various sociodemographic and behavioral factors.

resultsIn the analytic sample (N=7760), among the participants who did not use any PrEP in the past 12 months (n=5108, 66%), 54% (n=2445) reported willingness to start at least 1 PrEP option and 41% (n=1845) of participants showed interest in starting multiple PrEP options. Overall, the highest willingness was reported for on-demand PrEP (n=2235, 44%), followed by DO PrEP (n=2174, 43%) and LA PrEP (n=1482, 29%). LA PrEP was ranked first among those interested in multiple options. Characteristics associated with ranking LA PrEP as a first option to start PrEP versus DO or on-demand PrEP were region of residence (residing in the West vs Northeast), report of sexually transmitted infection diagnosis in the past year, report of illicit drug use other than marijuana in the past year, and prior awareness of LA PrEP. Among current DO PrEP users (n=2379, 31%), 58% (n=1386) were willing to switch to on-demand or LA PrEP, and LA PrEP was ranked first among participants who were open to switching to both options. Willingness to switch to LA PrEP was higher among those who used illicit drugs other than marijuana in the past year, who heard of LA PrEP prior to the survey, and those who took 15 or less doses of oral PrEP in the last 30 days.

conclusionsLA PrEP was the highest-ranked option among most MSM who were willing to try multiple options or switch from DO PrEP. These findings highlight that LA PrEP might fill coverage gaps among MSM who use illicit drugs, have had a recent sexually transmitted infection diagnosis, and have less than optimal DO PrEP adherence.

Indexed as

HIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisAdolescentAdultCross-Sectional StudiesHumansMaleMiddle AgedPatient PreferenceSurveys and QuestionnairesUnited StatesYoung AdultadherencegayHIVHIV preventionHIV treatmentillicit drug useinjectablelong-actingmen who have sex with menpreexposure prophylaxisreproductive healthsexual behaviorsexually transmitted infectionsociodemographicUnited States

Identifiers

PMID39536313
PMCPMC11602762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.